Semax

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analog of the adrenocorticotropic hormone (ACTH) fragment ACTH(4-10). It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and the Moscow State University over several decades, beginning in the 1980s. Semax has been approved in Russia since 2011 as a nasal spray for the treatment of stroke, cognitive disorders, peptic ulcers, and optic nerve disease — making it one of the few peptide-based nootropics with legitimate regulatory approval and clinical data in human patients.

What makes Semax scientifically interesting is that it derives from ACTH — a stress hormone — yet produces cognitive-enhancing and neuroprotective effects without stimulating adrenal cortisol production. The original ACTH(4-10) fragment was known to have cognitive effects independent of its adrenal stimulating properties, and Semax was engineered to preserve and enhance these neurotrophic effects while eliminating the hormonal (steroidogenic) activity entirely. This dissociation between cognitive and hormonal effects is the foundational insight behind Semax's development and a key differentiator from any attempt to use ACTH itself as a nootropic.

This guide covers what Semax is, how it works through neurotrophic factor modulation, what the human clinical data shows, how it compares to other nootropic peptides, and the honest limitations of its evidence base.

What Is Semax?

Semax's sequence (Met-Glu-His-Phe-Pro-Gly-Pro) incorporates the ACTH(4-7) core tetrapeptide (Met-Glu-His-Phe) that is responsible for ACTH's neurotropic effects, extended with Pro-Gly-Pro at the C-terminus. This C-terminal extension — the same Pro-Gly-Pro tripeptide used in Selank — dramatically increases metabolic stability, extending the half-life from minutes (for unmodified ACTH fragments) to hours.

Critically, Semax does not bind to the MC2R (melanocortin-2 receptor) on adrenal cells, which means it does not stimulate cortisol production. The concern that a compound derived from ACTH might elevate cortisol is reasonable but unfounded — the specific fragment used (positions 4-10) lacks the N-terminal sequence (positions 1-3) required for adrenal stimulation.

Semax is administered intranasally, similar to Selank and oxytocin nasal spray. The nasal route provides direct CNS access via olfactory and trigeminal nerve pathways, bypassing the blood-brain barrier. Russian formulations are available in two standard strengths: 0.1% (standard) and 1% (intensive, branded as Semax 1%).

How Semax Works: Mechanism of Action

BDNF Upregulation

Semax's most well-characterized mechanism involves potent upregulation of brain-derived neurotrophic factor (BDNF) expression, particularly in the hippocampus and cortex — the brain regions most critical for learning, memory formation, and cognitive function. BDNF is the primary neurotrophic factor supporting:

• Synaptic plasticity: BDNF drives long-term potentiation (LTP), the cellular mechanism underlying learning and memory
• Neuronal survival: BDNF protects neurons against damage from oxidative stress, excitotoxicity, and ischemia
• Neurogenesis: BDNF supports the generation of new neurons in the hippocampus
• Dendritic complexity: BDNF promotes dendritic branching, increasing the surface area available for synaptic connections

The magnitude of BDNF upregulation by Semax appears to be substantially greater than that produced by most other interventions, including exercise and standard antidepressants — though direct comparisons using identical methodologies are limited.

Nerve Growth Factor (NGF)

In addition to BDNF, Semax increases the expression of nerve growth factor (NGF), which is critical for the survival and maintenance of cholinergic neurons in the basal forebrain. These cholinergic neurons project to the hippocampus and cortex and are essential for attention and memory. Their degeneration is a hallmark of Alzheimer's disease.

Dopaminergic Modulation

Semax modulates dopaminergic neurotransmission, increasing dopamine turnover in the striatum and prefrontal cortex. This effect likely contributes to Semax's reported benefits for attention, motivation, and executive function. The dopaminergic modulation is more subtle than stimulant drugs — it modulates dopamine dynamics rather than flooding synapses — which may explain why Semax does not produce the euphoria, tolerance, or crash associated with traditional stimulants.

Serotonergic Modulation

Semax influences serotonergic neurotransmission, affecting the expression of genes encoding serotonin receptors and transporters. This mechanism may contribute to its reported mood-stabilizing and antidepressant-adjacent effects without the sexual dysfunction and emotional blunting associated with SSRIs.

Neuroprotective Mechanisms

Semax provides neuroprotection through multiple pathways:

• Anti-oxidant enhancement: Increases expression of endogenous antioxidant enzymes
• Anti-apoptotic signaling: Activates PI3K/Akt survival pathways
• Gene expression modulation: Semax influences the expression of hundreds of genes involved in neuronal survival, inflammation, and plasticity. Transcriptomic studies have shown that Semax modulates gene expression patterns associated with inflammation, neurodegeneration, and immune function in brain tissue.

Human Clinical Data

Stroke Treatment

Semax has been approved in Russia for acute ischemic stroke treatment and has been studied in multiple clinical trials:

Acute stroke studies: Clinical trials have demonstrated that Semax administered intranasally within the first hours of ischemic stroke improves neurological recovery compared to standard treatment alone. The benefits included better motor function recovery, improved cognitive outcomes, and reduced disability at follow-up.

Mechanism in stroke: In the ischemic brain, Semax's neuroprotective effects — BDNF upregulation, anti-apoptotic signaling, anti-inflammatory modulation — help preserve neurons in the ischemic penumbra (the area surrounding the dead core of the stroke where neurons are at risk but potentially salvageable).

Cognitive Enhancement in Healthy Subjects

Limited studies have examined Semax in healthy individuals:

• Improvements in attention and short-term memory have been reported
• EEG studies show changes in brain wave patterns consistent with enhanced cognitive processing
• Some studies suggest improved performance under stress or fatigue conditions

Optic Nerve Disease

Semax is approved in Russia for the treatment of optic nerve diseases, including optic atrophy. The mechanism involves neurotrophic support for retinal ganglion cells and optic nerve fibers. Clinical data shows improvement in visual acuity and visual field parameters with Semax treatment.

Limitations of Clinical Evidence

The same limitations that apply to Selank's evidence base apply to Semax:

• All clinical trials conducted in Russian institutions
• Limited independent replication by Western research groups
• Variable study design quality by Western standards
• Potential publication bias
• No FDA review of the clinical dataset

Semax Variants

Standard Semax (0.1%)

The standard formulation used for cognitive enhancement and mild cognitive disorders. Typical dosing is 2-3 drops per nostril, 2-3 times daily.

N-Acetyl Semax (NASA/NA-Semax)

An acetylated version with reportedly enhanced potency and longer duration of action. Popular in the Western nootropic community but with less published clinical data than standard Semax.

N-Acetyl Semax Amidate (NASA/NA-Semax Amidate)

A further modified version with both acetylation and amidation, claimed to have even greater stability and potency. Very limited published data; popularity driven primarily by user reports.

Semax vs. Other Nootropic Peptides

Semax vs. Selank

These two Russian-developed peptides are the most frequently compared, and some users combine them:

• Semax: ACTH-derived, primarily nootropic (cognitive enhancement, attention, memory), with secondary neuroprotective and mood effects. Stronger BDNF/NGF upregulation. Better for focus and cognitive performance.
• Selank: Tuftsin-derived, primarily anxiolytic (anxiety reduction) with secondary nootropic effects. Stronger GABA modulation. Better for anxiety with cognitive components.
• Combination: The "Semax + Selank stack" is popular in the nootropic community, targeting complementary pathways. Limited formal data on the combination.

Semax vs. Noopept

• Semax: Intranasal peptide, primarily neurotrophic mechanism (BDNF, NGF)
• Noopept: Oral dipeptide derivative, neurotrophic + glutamate modulation
• Key difference: Semax is a true peptide requiring intranasal delivery; Noopept is orally bioavailable. Both upregulate BDNF and NGF, but through different mechanisms.

Semax vs. Dihexa

• Semax: Established safety profile, human clinical data, regulatory approval
• Dihexa: No human data, unknown safety, specific cancer concerns from HGF/c-Met mechanism
• Recommendation: For anyone prioritizing evidence-based safety, Semax is dramatically more appropriate than Dihexa.

For a comprehensive comparison of nootropic peptides, also see our profiles on Cerebrolysin and Dihexa.

Side Effects and Safety

Reported Side Effects

Semax's safety profile from clinical use is remarkably clean:

• Nasal irritation: Mild irritation from intranasal delivery, the most commonly reported effect
• Headache: Occasional, typically mild
• Dizziness: Rare, usually transient
• Insomnia: If administered too late in the day (reflects cognitive-stimulating properties)

No Serious Adverse Events

No serious adverse events have been attributed to Semax in published clinical data or post-marketing surveillance. There are no reports of adrenal stimulation, cortisol elevation, tolerance, dependence, or withdrawal.

What We Don't Know

• Long-term safety beyond Russian surveillance periods
• Interactions with Western psychiatric medications
• Safety in pregnancy, lactation, and pediatric populations
• Effects in immunocompromised individuals

Dosing and Administration

Russian Approved Protocol

• Standard cognitive enhancement: Semax 0.1%, 2-3 drops per nostril, 2-3 times daily, for 10-14 day courses
• Acute stroke: Higher doses administered in clinical settings
• Course structure: Treatment courses with breaks between them; optimal inter-course interval not well-defined

Community Protocols

Western users typically follow:

• Standard Semax: 200-600 mcg intranasally, 1-3 times daily
• N-Acetyl Semax: 100-300 mcg intranasally, 1-2 times daily
• Course duration: 2-4 weeks on, 2-4 weeks off
• Timing: Morning and early afternoon to avoid potential sleep disruption

Legal Status

• Russia: Approved and commercially available
• United States: Not FDA-approved; available as a research chemical
• European Union: Not approved; available through research suppliers
• WADA: Not currently listed as a prohibited substance

The Bottom Line

Semax is arguably the best-supported nootropic peptide available, combining a well-characterized mechanism of action centered on BDNF and NGF upregulation, legitimate human clinical data (albeit Russian-only), regulatory approval in Russia for multiple neurological indications, and a remarkably clean safety profile across decades of clinical use.

Its limitations are the same limitations shared by its companion compound Selank — Russian-only evidence, no Western clinical trials, no FDA recognition, and the inherent uncertainty of relying on data from a regulatory system that doesn't fully meet Western evidence standards. These are real limitations, but they should be weighed against the reality that Semax has more human evidence than the vast majority of compounds in the research peptide space.

For anyone interested in evidence-based nootropic peptides, Semax represents one of the most reasonable options — better supported than Dihexa, with more cognitive specificity than Cerebrolysin, and complementary to Selank for individuals who want both cognitive enhancement and anxiolytic effects.

For related reading, see our profiles on Selank, Noopept, Dihexa, Cerebrolysin, and our peptide safety guide.

Frequently Asked Questions